Antimigraine drugs

被引：40

作者：

Diener, HC ^{[1
]}

Kaube, H ^{[1
]}

Limmroth, V ^{[1
]}

机构：

[1] Univ Essen Gesamthsch, Dept Neurol, D-45122 Essen, Germany

来源：

JOURNAL OF NEUROLOGY | 1999年 / 246卷 / 07期

关键词：

migraine attack; 5-HT1B/1D agonists; analgesics; ergotamine;

D O I：

10.1007/s004150050396

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Migraine is a paroxysmal disorder characterized by attacks of headache, nausea, vomiting, photophobia, phonophobia, and malaise. This review summarizes new treatment options for therapy of the acute attack. Mild or moderate migraine attacks are treated with antiemetics followed by analgesics such as aspirin, paracetamol, nonsteroidal antiinflammatory drugs, or antiemetics combined with ergotamine or dihydroergotamine. Sumatriptan, a specific serotonin (5-HT)(1B/D) agonist is used when attacks do not respond to ergotamine, or when intolerable side effects occur. The new migraine drugs zolmitriptan, naratriptan, rizatriptan, and eletriptan differ slightly in their pharmacological profiles, which translates into minor differences in efficacy, headache recurrence, and side effects. New drugs in migraine prophylaxis include cyclandelate, valproic acid and magnesium.

引用

页码：515 / 519

页数：5

共 30 条

[1]

BECKER WJ, 1995, CEPHALALGIA, V15, P239

[2] Pilot study of MK-462 in migraine [J].

Cutler, NR ;

Claghorn, J ;

Sramek, JJ ;

Block, G ;

Panebianco, D ;

Cheng, H ;

Olah, TV ;

Reines, SA .

CEPHALALGIA, 1996, 16 (02) :113-116

[3] Cyclandelate in the prophylaxis of migraine: A randomized, parallel, double-blind study in comparison with placebo and propranolol [J].

Diener, HC ;

Foh, M ;

Iaccarino, C ;

Wessely, P ;

Isler, H ;

Strenge, H ;

Fischer, M ;

Wedekind, W ;

Taneri, Z .

CEPHALALGIA, 1996, 16 (06) :441-447

[4]

DIENER HC, 1994, REV CONTEMP PHARMACO, V5, P271

[5]

DIENER HC, 1995, 6 HEAD RES SEM COP N

[6]

Earl Nancy L., 1997, V6, P267

[7]

FARKKILA M, 1996, CEPHALALGIA, V16, P387

[8]

FLETCHER PE, 1997, HEADACHE TREATMENT T, P273

[9] Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)(1B/D) receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine? [J].

Goadsby, PJ ;

Hoskin, KL .

PAIN, 1996, 67 (2-3) :355-359

[10] Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat [J].

Goadsby, PJ ;

Knight, YE .

CEPHALALGIA, 1997, 17 (03) :153-158

← 1 2 3 →